Xeris Biopharma Holdings (XERS) Current Leases (2022 - 2026)

Xeris Biopharma Holdings has reported Current Leases for 5 years, with the latest figure at $6.3 million in Q1 2026.

• For the quarter ending Q1 2026, Current Leases rose 2.52% year-over-year to $6.3 million; the trailing twelve-month figure through Mar 2026 stood at $6.3 million (up 2.52% YoY), and the FY2025 full-year result was $6.2 million, up 2.5% from the prior year.
• Current Leases for Q1 2026 stood at $6.3 million, up from $6.2 million in the prior quarter.
• The five-year high for Current Leases was $6.3 million in Q1 2026, with the low at $1.4 million in Q1 2023.
• Historically, Current Leases has averaged $4.6 million across 5 years, with a median of $5.7 million in 2024.
• Annual changes were most pronounced in 2024 — Current Leases jumped 219.34% — and 2025, when it climbed 2.5%.
• Xeris Biopharma Holdings' Current Leases stood at $1.6 million in 2022, then jumped by 121.2% to $3.5 million in 2023, then jumped by 73.96% to $6.1 million in 2024, then increased by 2.5% to $6.2 million in 2025, then advanced by 0.63% to $6.3 million in 2026.
• The last three Current Leases figures came in at $6.3 million (Q1 2026), $6.2 million (Q4 2025), and $6.2 million (Q3 2025), per Business Quant data.